Literature DB >> 9198119

Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis.

F R Rosendaal1.   

Abstract

Thrombosis occurs most often as myocardial infarction, cerebral infarction or venous thromboembolism, ie, deep-vein thrombosis and pulmonary embolism. The incidence of all types of thrombosis is strongly dependent on age. Among young individuals, up to age 40, venous thrombosis is the most common form of thrombosis. The risk factors for arterial and venous thrombosis differ, and among the latter disorders of hemostasis appear to be more prominent. In children venous thrombosis appears almost exclusively in association with venous catheters, with an exception of the renal vein thrombosis of the newborn, which has an unknown etiology. In young adults, the risk factors for venous thrombosis are essentially the same as in older individuals, excepting oral contraceptives, pregnancy and puerperium which are limited to young women. In young women, most venous thrombotic events can be attributed to oral contraceptives. Venous thrombosis is a multicausal disease: more than one risk factor needs to be present before thrombosis occurs. The younger an individual, the more risk factors are required to precipitate thrombosis: in children often three or four, and in young adults often two or more.

Entities:  

Mesh:

Year:  1997        PMID: 9198119

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  39 in total

1.  How to treat women with antiphospholipid antibodies in pregnancy?

Authors:  R H Derksen; P G De Groot; H K Nieuwenhuis; G C Christiaens
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

Review 2.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

3.  Clinical Presentation, Imaging and Treatment of Cerebral Venous Thrombosis (CVT).

Authors:  S K Lee; B S Kim; K G Terbrugge
Journal:  Interv Neuroradiol       Date:  2004-10-20       Impact factor: 1.610

4.  An age-related decrease in factor V Leiden frequency among Polish subjects.

Authors:  G Adler; M Parczewski; E Czerska; B Loniewska; M Kaczmarczyk; J Gumprecht; W Grzeszczak; A Szybinska; M Mossakowska; A Ciechanowicz
Journal:  J Appl Genet       Date:  2010       Impact factor: 3.240

5.  Venous thrombosis at altitude presents with distinct biochemical profiles: a comparative study from the Himalayas to the plains.

Authors:  Amit Prabhakar; Tathagata Chatterjee; Nitin Bajaj; Tarun Tyagi; Anita Sahu; Neha Gupta; Babita Kumari; Velu Nair; Bhuvnesh Kumar; Mohammad Zahid Ashraf
Journal:  Blood Adv       Date:  2019-11-26

6.  Extrahepatic portal vein thrombosis in children and adolescents: Influence of genetic thrombophilic disorders.

Authors:  Andrea Pietrobattista; Matteo Luciani; Juan G Abraldes; Manila Candusso; Simona Pancotti; Massimo Soldati; Lidia Monti; Giuliano Torre; Valerio Nobili
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

Review 7.  Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era.

Authors:  Nancy F Crum-Cianflone; Jhamillia Weekes; Mary Bavaro
Journal:  AIDS Patient Care STDS       Date:  2008-10       Impact factor: 5.078

Review 8.  Long-cycle treatment with oral contraceptives.

Authors:  Inka Wiegratz; Herbert Kuhl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.

Authors:  Troy C Sarich; Renli Teng; Gary R Peters; Maria Wollbratt; Robert Homolka; Mia Svensson; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.

Authors:  Gunnar Fager; Marie Cullberg; Maria Eriksson-Lepkowska; Lars Frison; Ulf G Eriksson
Journal:  Eur J Clin Pharmacol       Date:  2003-07-04       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.